Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems Inc. (NYSE: VEEV) is a cloud software company focused on the global life sciences industry, and its news flow reflects activity across commercial, R&D, quality, and corporate initiatives. Company announcements frequently highlight new product capabilities in its industry cloud for life sciences, including developments in Veeva AI, Vault CRM, Veeva Development Cloud, Veeva Quality Cloud, and solutions such as Veeva Environmental Monitoring and Veeva Basics.
Investors and industry professionals following VEEV news can see updates on strategic partnerships with major life sciences companies, such as long-term enterprise agreements and expanded use of Vault CRM by large pharmaceutical and biopharmaceutical organizations. Veeva also issues releases on its work with emerging biotechs, including adoption of Veeva Basics to standardize operations across clinical, regulatory, and quality.
Veeva’s news includes information on AI-driven capabilities like Veeva AI Agents for Vault CRM and PromoMats, covering agents such as Free Text Agent, Voice Agent, Pre-call Agent, Quick Check Agent, and Content Agent. These updates describe how the company embeds industry-specific AI into its applications to support productivity, compliance, and customer engagement in life sciences.
In addition, Veeva regularly publishes earnings results, financial outlooks, and capital allocation decisions, such as the authorization of a share repurchase program reported in an 8-K filing. The company also announces participation in investor conferences and provides details on its role as a Public Benefit Corporation. This news page aggregates these releases so readers can track product milestones, customer agreements, AI developments, financial updates, and corporate governance disclosures related to VEEV.
Veeva Systems (NYSE: VEEV) announced that ConvaTec has chosen Veeva Vault CDMS for electronic data capture in a study focused on detecting wound infections. This proof-of-concept study will evaluate the effectiveness of a combination of biomarkers—wound pH, human neutrophil elastase (HNE), and myeloperoxidase (MPO)—to detect infections. The international study aims to enroll 75 to 90 subjects over approximately 20 weeks. Veeva MedTech supports ConvaTec's efforts with its unified data management solution.
Emmes has partnered with Veeva Systems (NYSE: VEEV) to standardize on Veeva Development Cloud applications, enhancing speed and compliance in clinical research. This collaboration aims to improve operational efficiency across various functional areas, aiding in the growth of Emmes as it expands into new markets. Veeva's cloud solutions will facilitate better collaboration with sponsors and regulatory compliance. Emmes plans to implement several Veeva applications, thereby establishing a unified technology platform for effective clinical and quality management.
Veeva Systems (NYSE: VEEV) announced the launch of Veeva Vault Validation Management, a new application designed to enhance validation lifecycle management for life sciences companies. This solution streamlines validation processes, reduces manual efforts, and supports electronic execution to improve compliance and efficiency. Veeva Vault Validation Management integrates with other Veeva Vault Quality Suite applications, enabling better documentation and data integrity. The application is expected to be available in the second half of 2022, aiming to optimize quality management across the life sciences value chain.
Veeva Systems (NYSE: VEEV) announced the 2021 Veeva R&D and Quality Summit Connect, featuring keynote speakers from Bristol Myers Squibb, GSK, and Roche. This online event on October 14, 2021, aims to enhance knowledge sharing in life sciences, with over 75 sessions focusing on advancements in digital trials. Industry leaders will discuss operational improvements and compliance strategies. Veeva emphasizes its commitment to innovation and customer success, serving over 1,100 clients.
Veeva Systems (NYSE: VEEV) has announced its 2021 Quality & Regulatory Global Summit, set to begin on October 18, 2021. The virtual summit will feature over 15 sessions with industry leaders from companies like Unilever, BASF, and Estée Lauder. Discussions will focus on modernizing business initiatives including product compliance and sustainability. The event is complimentary for Veeva customers and qualified industry professionals. Veeva, known for its cloud software solutions, aims to support industries like consumer goods and chemicals in overcoming regulatory challenges.
Veeva Systems reported a strong second quarter for fiscal 2022, with total revenues of $455.6 million, marking a 29% year-over-year increase. Subscription services revenues also rose to $366.4 million, up 29%. Operating income was $124.6 million, a 38% increase compared to the prior year. Non-GAAP net income increased by 31% to $152.7 million, with diluted net income per share at $0.67. Veeva's outlook for the third quarter projects revenues between $464 and $466 million and for the fiscal year, between $1,830 and $1,835 million.
Veeva Systems (NYSE: VEEV) announces that B. Braun SE has adopted the Veeva Vault Clinical Operations Suite to enhance clinical study management and payments to partner sites globally. This collaboration aims to improve efficiency and oversight in clinical trials, allowing B. Braun to conduct more studies at a faster pace. The integration includes Veeva's solutions for study management and payments, aiding compliance and reducing administrative burdens. The partnership signifies a step in B. Braun's digital transformation and commitment to advancing healthcare.
Veeva Systems will release its financial results for the second fiscal quarter, concluding on July 31, 2021, after market close on September 1, 2021. A conference call and webcast will be held on the same day at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results. Prepared remarks will be available on Veeva's investor relations website around 1:05 p.m. PT (4:05 p.m. ET). This quarterly release comes as Veeva continues to serve over 1,000 customers globally in the life sciences sector.
Veeva Systems (NYSE: VEEV) announced its acquisition of Learnaboutgmp, a premier provider of accredited GxP training for life sciences, on August 3, 2021. This acquisition combines Learnaboutgmp's extensive eLearning library, featuring over 170 course titles and 450 microlearning assets, with Veeva's Vault Training, enhancing training efficiency and compliance for clients. Learnaboutgmp will continue its operations independently under its founder, maintaining its presence in both Ireland and the United States, while aiming to address growing compliance needs in the industry.
Veeva Systems announced the addition of 11 new therapeutic areas to its customer intelligence platform, Veeva Link, now covering 12 areas including oncology. The platform provides curated expert profiles and real-time insights to enhance engagement between life sciences teams and global experts. Key areas expanded include cardiology, neurology, and respiratory diseases. Veeva aims to set the industry standard in real-time customer intelligence, supporting better research and patient care. A summit on June 10, 2021, will showcase how Veeva Link aids pharma companies in personalizing customer interactions.